Circulating Biomarkers for Detection of Ovarian Cancer and Predicting Cancer Outcomes

Overview

Journal Br J Cancer

Specialty Oncology

Date 2013 Dec 25

PMID 24366298

Citations 81

Authors

I Shapira

M Oswald

J Lovecchio

H Khalili

A Menzin

J Whyte

L Dos Santos

S Liang

T Bhuiya

M Keogh

C Mason

K Sultan

D Budman

P K Gregersen

A T Lee

Affiliations

Soon will be listed here.

Abstract

Background: Securing a diagnosis of ovarian cancer and establishing means to predict outcomes to therapeutics remain formidable clinical challenges. Early diagnosis is particularly important since survival rates are markedly improved if tumour is detected early.

Methods: Comprehensive miRNA profiles were generated on presurgical plasma samples from 42 women with confirmed serous epithelial ovarian cancer, 36 women diagnosed with a benign neoplasm, and 23 comparably age-matched women with no known pelvic mass.

Results: Twenty-two miRNAs were differentially expressed between healthy controls and the ovarian cancer group (P<0.05), while a six miRNA profile subset distinguished presurgical plasma from benign and ovarian cancer patients. There were also significant differences in miRNA profiles in presurgical plasma from women diagnosed with ovarian cancer who had short overall survival when compared to women with long overall survival (P<0.05).

Conclusion: Our preliminary data support the utility of circulating plasma miRNAs to distinguish women with ovarian cancer from those with a benign mass and identify women likely to benefit from currently available treatment for serous epithelial ovarian cancer from those who may not.

Citing Articles

Role of microRNA in Sex Steroid Hormones Signaling and Its Effect in Regulation of Endometrial, Ovarian, and Cervical Cancer: A Literature Review.

Fadl J, Aljuhani R, Albog Y, Khraisat A, Alsubaie K Cureus. 2024; 16(2):e54773.

PMID: 38523927 PMC: 10961145. DOI: 10.7759/cureus.54773.

Differential microRNA Expression Analysis in Patients with HPV-Infected Ovarian Neoplasms.

Jarych D, Mikulski D, Wilczynski M, Wilczynski J, Kania K, Hareza D Int J Mol Sci. 2024; 25(2).

PMID: 38255835 PMC: 10815566. DOI: 10.3390/ijms25020762.

Identification of stably expressed microRNAs in plasma from high-grade serous ovarian carcinoma and benign tumor patients.

Petersen P, Lopacinska-Jorgensen J, Hogdall C, Hogdall E Mol Biol Rep. 2023; 50(12):10235-10247.

PMID: 37934368 PMC: 10676310. DOI: 10.1007/s11033-023-08795-6.

Functions, mechanisms, and clinical applications of lncRNA LINC00857 in cancer pathogenesis.

Aldayyeni H, Hjazi A, Shahab S, Gupta J, Alsaab H, Motea Y Hum Cell. 2023; 36(5):1656-1671.

PMID: 37378889 DOI: 10.1007/s13577-023-00936-0.

Peritoneal Fluid Analysis of Advanced Ovarian Cancers after Hyperthermic Intraperitoneal Chemotherapy.

Chen W, Chang T, Chou H, Cheng M, Hong J, Hsieh Y Int J Mol Sci. 2023; 24(11).

PMID: 37298699 PMC: 10253890. DOI: 10.3390/ijms24119748.

References

Anderson G, McIntosh M, Wu L, Barnett M, Goodman G, Thorpe J . Assessing lead time of selected ovarian cancer biomarkers: a nested case-control study. J Natl Cancer Inst. 2010; 102(1):26-38. PMC: 2802285. DOI: 10.1093/jnci/djp438. View

Habeeb O, Goodglick L, Soslow R, Rao R, Gordon L, Schirripa O . Epithelial membrane protein-2 expression is an early predictor of endometrial cancer development. Cancer. 2010; 116(20):4718-26. PMC: 2950887. DOI: 10.1002/cncr.25259. View

Dahiya N, Morin P . MicroRNAs in ovarian carcinomas. Endocr Relat Cancer. 2009; 17(1):F77-89. PMC: 2856347. DOI: 10.1677/ERC-09-0203. View

Freije W, Castro-Vargas F, Fang Z, Horvath S, Cloughesy T, Liau L . Gene expression profiling of gliomas strongly predicts survival. Cancer Res. 2004; 64(18):6503-10. DOI: 10.1158/0008-5472.CAN-04-0452. View

Resnick K, Alder H, Hagan J, Richardson D, Croce C, Cohn D . The detection of differentially expressed microRNAs from the serum of ovarian cancer patients using a novel real-time PCR platform. Gynecol Oncol. 2008; 112(1):55-9. DOI: 10.1016/j.ygyno.2008.08.036. View

Schmittgen T, Livak K . Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc. 2008; 3(6):1101-8. DOI: 10.1038/nprot.2008.73. View

Pouliot L, Chen Y, Bai J, Guha R, Martin S, Gottesman M . Cisplatin sensitivity mediated by WEE1 and CHK1 is mediated by miR-155 and the miR-15 family. Cancer Res. 2012; 72(22):5945-55. PMC: 3500396. DOI: 10.1158/0008-5472.CAN-12-1400. View

Dahiya N, Sherman-Baust C, Wang T, Davidson B, Shih I, Zhang Y . MicroRNA expression and identification of putative miRNA targets in ovarian cancer. PLoS One. 2008; 3(6):e2436. PMC: 2410296. DOI: 10.1371/journal.pone.0002436. View

Piver M, MALFETANO J, Baker T, Hempling R . Five-year survival for stage IC or stage I grade 3 epithelial ovarian cancer treated with cisplatin-based chemotherapy. Gynecol Oncol. 1992; 46(3):357-60. DOI: 10.1016/0090-8258(92)90232-8. View

10.

Chung Y, Bae H, Song J, Lee J, Lee N, Kim T . Detection of microRNA as novel biomarkers of epithelial ovarian cancer from the serum of ovarian cancer patients. Int J Gynecol Cancer. 2013; 23(4):673-9. DOI: 10.1097/IGC.0b013e31828c166d. View

11.

Zhang L, Volinia S, Bonome T, Calin G, Greshock J, Yang N . Genomic and epigenetic alterations deregulate microRNA expression in human epithelial ovarian cancer. Proc Natl Acad Sci U S A. 2008; 105(19):7004-9. PMC: 2383982. DOI: 10.1073/pnas.0801615105. View

12.

Olive V, Jiang I, He L . mir-17-92, a cluster of miRNAs in the midst of the cancer network. Int J Biochem Cell Biol. 2010; 42(8):1348-54. PMC: 3681296. DOI: 10.1016/j.biocel.2010.03.004. View

13.

Turchinovich A, Weiz L, Langheinz A, Burwinkel B . Characterization of extracellular circulating microRNA. Nucleic Acids Res. 2011; 39(16):7223-33. PMC: 3167594. DOI: 10.1093/nar/gkr254. View

14.

. Integrated genomic analyses of ovarian carcinoma. Nature. 2011; 474(7353):609-15. PMC: 3163504. DOI: 10.1038/nature10166. View

15.

Arroyo J, Chevillet J, Kroh E, Ruf I, Pritchard C, Gibson D . Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. Proc Natl Acad Sci U S A. 2011; 108(12):5003-8. PMC: 3064324. DOI: 10.1073/pnas.1019055108. View

16.

Wadehra M, Natarajan S, Seligson D, Williams C, Hummer A, Hedvat C . Expression of epithelial membrane protein-2 is associated with endometrial adenocarcinoma of unfavorable outcome. Cancer. 2006; 107(1):90-8. DOI: 10.1002/cncr.21957. View

17.

Siegel R, Naishadham D, Jemal A . Cancer statistics, 2012. CA Cancer J Clin. 2012; 62(1):10-29. DOI: 10.3322/caac.20138. View

18.

Wylie D, Shelton J, Choudhary A, Adai A . A novel mean-centering method for normalizing microRNA expression from high-throughput RT-qPCR data. BMC Res Notes. 2011; 4:555. PMC: 3267743. DOI: 10.1186/1756-0500-4-555. View

19.

Shen J, Stass S, Jiang F . MicroRNAs as potential biomarkers in human solid tumors. Cancer Lett. 2012; 329(2):125-36. PMC: 3552101. DOI: 10.1016/j.canlet.2012.11.001. View

20.

Hausler S, Keller A, Chandran P, Ziegler K, Zipp K, Heuer S . Whole blood-derived miRNA profiles as potential new tools for ovarian cancer screening. Br J Cancer. 2010; 103(5):693-700. PMC: 2938264. DOI: 10.1038/sj.bjc.6605833. View